Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
42 results about "Desmosome" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A desmosome (/ˈdɛzməˌsoʊm/; "binding body"), also known as a macula adherens (plural: maculae adherentes) (Latin for adhering spot), is a cell structure specialized for cell-to-cell adhesion. A type of junctional complex, they are localized spot-like adhesions randomly arranged on the lateral sides of plasma membranes. Desmosomes are one of the stronger cell-to-cell adhesion types and are found in tissue that experience intense mechanical stress, such as cardiac muscle tissue, bladder tissue, gastrointestinal mucosa, and epithelia.
Compositions and methods for treating insulin resistance and diabetes mellitus
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Compositions and methods for treating multiple sclerosis
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Anterior ocular-associated cell sheet, three-dimensional construct and process for producing the same
InactiveUS20060240552A1Few structuresNervous system cellsMammal material medical ingredientsDissolutionCultured cell
An anterior ocular segment related cell sheet or three-dimensional structure that have only a few structural defects as they have been recovered retaining the intercellular desmosome structure and the basement membrane-like protein between cell and substrate. The anterior ocular segment related cell sheet or three-dimensional structure is produced by a process comprising the steps of cultivating cells on a cell culture support comprising a substrate having its surface covered with a temperature responsive polymer having an upper or lower critical dissolution temperature of 0-80° C. with respect to water, optionally stratifying the layer of cultured cells by the usual method, and thereafter, (1) adjusting the temperature of the culture solution to either above the upper critical dissolution temperature or below the lower critical dissolution temperature, and further optionally (2) bringing the cultured anterior ocular segment related cell sheet or three-dimensional structure into close contact with a polymer membrane, and (3) detaching the sheet or three-dimensional structure together with the polymer membrane.
Owner:CELLSEED
Compounds and methods for modulating desmosomal cadherin-mediated functions
InactiveUS20040229811A1NanotechCell receptors/surface-antigens/surface-determinantsAntigenCell adhesion
Modulating agents for inhibiting or enhancing desmosomal cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a desmosomal cadherin CAR sequence; (b) a non-peptide mimetic of a desmosomal cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a desmosomal cadherin CAR sequence; and / or (d) a polynucleotide encoding a polypeptide that comprises a desmosomal cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating desmosomal cadherin-mediated cell adhesion in a variety of contexts are also provided.
Owner:ADHEREX TECH
Tissue engineered skin with basilar membrane and construction method thereof
InactiveCN101954124ASimple methodEasy to get materialsArtificial cell constructsVertebrate cellsEpidermis structureManufacturing technology
The invention relates to the technical fields of tissue engineering and medical wound repair. At present, a living skin substitute constructed by using the materials of polylactic acid, polyglycolic acid, collagen, hyaluronic acid, and the like as a dermic bracket has the defects that on one hand, host materials are difficult to extract, the living skin substitute has complicated manufacturing technology and is expensive in cost and difficult to widely popularize and apply clinically; and on the other hand, the living skin substitute does not have a skin basilar membrane structure so that healed skin does not resist pressure and wear, and the living skin has unfirm adhesion to the epidermis and is easy to shed and break or form water blisters so that the structural and morphological development of the normal epidermis is influenced; and allogeneic acellular dermis is taken from cadaver skin and is limited in sources and expensive in cost, and thus clinical application is limited. The invention aims at providing a skin substitute which uses surface-finished and modified amnion as the basilar membrane and blood plasma as stroma, which has the advantages of wide material sources, low cost and simple preparation method. An animal experiment proves that the complete basilar membrane and hemidesmosomes can be retained in in-vivo transplantation, and the formation of an epidermal structural form is accelerated and promoted.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
InactiveUS20060241075A1Improve bioavailabilityMinimize the possibilitySugar derivativesGenetic material ingredientsDesmoyokinGLYAT gene
This invention relates to compounds, compositions, and methods useful for modulating Desmoglein (e.g, DSG1, DSG2, DSG3, and / or DSG4) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Desmoglein gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of Desmoglein genes.
Owner:SIRNA THERAPEUTICS INC
Cell sheet engineering and preparation method thereof
InactiveCN101629162AGet the effect of graftingNo deformation damageTissue cultureProsthesisPoly(N-isopropylacrylamide)Cell sheet
The invention belongs to the field of tissue engineering, in particular to a cell sheet engineering and a preparation method thereof. The cell sheet is prepared with the following methods: firstly, an electron accelerator is used for radiating on the surface of the cell culture supporter for synthesizing poly-N-isopropylacrylamide; then, temperature is controlled to cause the poly-N-isopropylacrylamide to be hydrophobicity phase, and cells are cultured on the phase; temperature is changed to cause hydrogel to be hydrophilic phase; with the method that a polymeric membrane is used for adsorbing or a clamp is used for clamping to separate the cell sheet engineering. Obtained cell sheets are cultivated by multiple stratification, or protein adhering liquid is used for adhering to obtain multiple layers of cell sheets. The cell sheet obtained by the invention can keep desmosome structure between cells, ZO-1 tight connection structure and the connection structure between other cells, can keep basement membrane protein and a plurality of components thereof relative to adhesion, such as integrin and the like and has certain strength.
Owner:JINAN UNIVERSITY +1
Functional desmosome profile control agent and preparation method and application thereof
ActiveCN105802597AWith water swellingImprove water absorptionFluid removalDrilling compositionEngineeringOil well
The invention provides a functional desmosome profile control agent and a preparation method and application thereof.The functional desmosome profile control agent is prepared from, by weight, 0.5%-11% of functional desmosome profile control agent particles, 0.1%-1% of guanidine gum and the balance water, wherein the total weight of the functional desmosome profile control agent is 100%, the functional desmosome profile control agent particles comprise inner cores, thermal swelling crosslinking resin films and semi-permeable protective films, the surfaces of the inner cores are wrapped by the thermal swelling crosslinking resin films, and the surfaces of the thermal swelling crosslinking resin films are wrapped by the semi-permeable protective films.The invention further provides the preparation method of the functional desmosome profile control agent and application of the functional desmosome profile control agent in oil well deep profile control.The functional desmosome profile control agent has the characteristics of temperature resisting, salt resisting, swelling delaying, crosslinking under heating and the like and is a novel profile control agent which is convenient to construct and easy to operate.
Owner:北京石大瑞伽石油技术开发有限公司
Anti-Autoimmune Antibodies for Treatment of Pemphigus
ActiveUS20100135948A1Inhibit expressionInhibit bindingAntibacterial agentsOrganic active ingredientsDesmoyokinAutoantibody production
This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for both pemphigus vulgaris and pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Methods and systems for adenovirus interaction with desmoglein 2 (DSG2)
ActiveUS20110305634A1Good curative effectImprove efficacyAntibacterial agentsVirusesBiologyDesmoglein-2
Owner:UNIV OF WASHINGTON CENT FOR COMMERICIALIZATION
Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy
An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.
Owner:BIONTECH AG
Mediators of epithelial adhesion and their role in cancer and skin disorders
InactiveUS20060286090A1Avoid developmentCell receptors/surface-antigens/surface-determinantsGenetic material ingredientsCancer preventionDisease
Perp is shown to mediate stratified epithelial development in vivo. Perp localizes specifically to desmosomes, adhesion junctions important for tissue integrity. In some embodiments of the invention, detection of autoantibodies specific for perp find use in the diagnosis of pemphigus. In other embodiments, agent that upregulate or mimic perp function are useful in treatment of such blistering diseases. In another embodiment, agents that inhibit perp function are useful in treating and preventing cancer.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Compositions and methods for treating multiple sclerosis
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
Disclosed is a method for the diagnosis of cancer, which is characterized by detecting a DSG3 protein. It is found that the increase in the expression level of DSG3 is observed in lung cancer highly frequently at a gene or protein level. The method can be effected by using an antibody capable of recognizing a DSG3 protein. Also disclosed are a pharmaceutical composition, a cell proliferation inhibitor and an anti-cancer agent, each comprising an antibody capable of binding to DSG3 as an active ingredient. Further disclosed a method for inducing the cytopathy in a DSG3-expressing cell and a method for inhibiting the proliferation of a DSG3-expressing cell, each by contacting the DSG3-expressing cell with an antibody capable of binding to DSG3.
Owner:FORERUNNER PHARMA RES CO LTD +1
Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy
InactiveUS20110014628A1Worsened courseTumor rejection antigen precursorsPeptide/protein ingredientsNucleotideExon
An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.
Owner:GANYMED PHARMA AG
Functional desmosome temporary plugging agent and preparation method thereof
ActiveCN105441050AHigh viscosityAchieve resistance increaseDrilling compositionCellulosePotassium formate
The invention provides a functional desmosome temporary plugging agent and a preparation method thereof. Counting the total mass of the functional desmosome temporary plugging agent at 100 percent, the functional desmosome temporary plugging agent is prepared from the following raw materials by weight percent: 45 to 58 percent of water, 0.2 to 0.4 percent of sodium carbonate, 0.05 to 0.1 percent of sodium hydroxide, 0.1 to 0.2 percent of methanol, 0.1 to 0.2 percent of octane, 0.3 to 0.5 percent of D-glucuronic acid, 0.04 to 0.1 percent of lauryl sodium sulfate, 1.3 to 1.7 percent of polyanionic celluloses, 0.2 to 0.4 percent of carboxymethyl celluloses, 0.2 to 0.5 percent of methyl tert-butyl ether and 40 to 50 percent of potassium formate, wherein the sum of the mass percent of all raw materials in the functional desmosome temporary plugging agent is 100 percent. The invention also provides the preparation method of the functional desmosome temporary plugging agent. The functional desmosome temporary plugging agent belongs to an oil-gas layer temporary plugging agent integrating shielding temporary plugging, oil-gas layer protection, leakage prevention and leakage plugging.
Owner:SONGYUAN MARINE PETROLEUM TECH CO LTD
Compounds and methods for modulating functions of nonclassical cadherins
InactiveUS7476509B2Inhibiting endometriosisEnhancing inhaled compound deliveryBiocideCell receptors/surface-antigens/surface-determinantsCell adhesionAdhesion process
Modulating agents and methods for enhancing or inhibiting nonclassical cadherin-mediated functions, such as atypical or desmosomal cadherin-mediated functions, are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of an atypical and / or desmosomal cadherin, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and / or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and / or support material.
Owner:ADHEREX TECH
Compositions and methods for treating insulin resistance and diabetes mellitus
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Compositions and methods for treatment of taupathy
Owner:REVALESIO CORP
Cellular attachment to trans-epithelial appliances
InactiveUSRE36844E1Bioreactor/fermenter combinationsBiological substance pretreatmentsJunctional epitheliumProtein composition
A trans-epithelial appliance having a hemidesmosome formation-inducing protein composition derived from rat bladder carcinoma cells deposited thereon. This composition stimulates cell attachment and may be either the cell matrix or a soluble factor isolated from the conditioned medium. The appliance will be useful for diminishing inflammation and / or infection at the site of entry of the appliance. The appliance may also be used to stimulate gum junctional epithelium adhesion in the treatment of gingivitis and periodontitis. The composition may be used to maintain tissues ex vivo.
Owner:DESMOS
Composition for inhibiting melanin pigmentation and application thereof
ActiveCN107157787ATo promote metabolismFacilitate strippingCosmetic preparationsToilet preparationsHypopigmentationDendritic cell
The invention relates to a composition for inhibiting melanin pigmentation and an application thereof. The composition comprises nicotinamide, inositol, papain and hesperidin extract products, The composition employs nicotinamide and inositol for blocking melanin and transferring black particles to cutin cells through dendritic cells, keratinocyte metabolism is accelerated; lipid-coated papain is employed, peeling and removal of dead cells on a cutin surface layer can be promoted, the melanin is discharged with shedding of cutin cells, update of the cuticle cells is excited; the hesperidin extract product can enhance the function for beautifying the skin, the cornification cellular structure is lifted, desmoplakin and keratin distribution can be improved, and the expression of CASEPASE-14 protein is promoted.
Owner:HUNAN YUJIA COSMETICS MFG CO LTD
Compositions and methods of chimeric autoantibody receptor T cells
ActiveUS10301370B2Polypeptide with localisation/targeting motifImmunoglobulin superfamilyT cellVirology
The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Blood cell separation
InactiveUS20100167328A1Good curative effectBioreactor/fermenter combinationsBiological substance pretreatmentsCell-Extracellular MatrixVinculin
There is provided a method of isolating foetal cells from an isolated sample of maternal blood, the method comprising identifying cells having a different expression pattern of at least one foetal marker compared to the expression pattern of the marker in an equivalent maternal cell and selecting the identified cells, characterised in that the foetal marker is selected from: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, Extracellular matrix protein 2 precursor protein, uncharacterised protein Cxorf57, Peroxiredoxin 1, Peroxiredoxin 2. There is also provided a method of cultivating foetal cells and a foetal cell isolation kit.
Owner:UNIV OF THE WEST OF ENGLAND BRISTOL
Composition for Detecting Undifferentiated Human Pluripotent Stem Cell, Monoclonal Antibody 6-1 and Use Thereof
ActiveUS20160097096A1Microbiological testing/measurementBiological material analysisMonoclonal antibodyBiological activation
The present invention relates to a composition for detecting the undifferentiated human pluripotent stem cells comprising an agent useful for measuring the level of Desmoglein 2 (Dsg 2) mRNA or the protein thereof, a kit for detecting the undifferentiated human pluripotent stem cells comprising the said composition, a method for detecting the undifferentiated human pluripotent stem cells containing the step of measuring the level of Desmoglein 2 mRNA or the protein thereof, a method for evaluating the differentiation of human pluripotent stem cells and thereafter for separating the undifferentiated human pluripotent stem cells, a method for reducing the undifferentiated status of human pluripotent stem cells by inhibiting the expression or activation of Desmoglein 2, and a monoclonal antibody binding specifically to human Desmoglein 2.
Owner:KOREA RES INST OF BIOSCI & BIOTECH
Compositions and methods for treating inflammation
Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.
Owner:REVALESIO CORP
Method for detecting lung squamous cell carcinoma
ActiveUS10502743B2The method is simple and fastHigh sensitivityCell receptors/surface-antigens/surface-determinantsBiological material analysisLung squamous cell carcinomaGlycoprotein
The present invention provides a method by which lung squamous cell carcinoma can be detected in a simple and prompt manner with high detection performance; and the like. The method according to the present invention detects lung squamous cell carcinoma by an assessment including the steps of: (1) performing measurement of the desmoglein 3 content in a blood sample collected from a subject; and (2) comparing the desmoglein 3 content determined by the measurement with the desmoglein 3 content in a blood sample collected from a healthy individual so as to estimate the presence of lung squamous cell carcinoma in the subject when the desmoglein 3 content is higher in the blood sample collected from the subject.
Owner:CHUGAI PHARMA CO LTD +1
Method for detecting lung squamous cell carcinoma
ActiveUS20150276749A1The method is simple and fastHigh sensitivityCell receptors/surface-antigens/surface-determinantsBiological material analysisLung squamous cell carcinomaGlycophorin
The present invention provides a method by which lung squamous cell carcinoma can be detected in a simple and prompt manner with high detection performance; and the like. The method according to the present invention detects lung squamous cell carcinoma by an assessment including the steps of: (1) performing measurement of the desmoglein 3 content in a blood sample collected from a subject; and (2) comparing the desmoglein 3 content determined by the measurement with the desmoglein 3 content in a blood sample collected from a healthy individual so as to estimate the presence of lung squamous cell carcinoma in the subject when the desmoglein 3 content is higher in the blood sample collected from the subject.
Owner:CHUGAI PHARMA CO LTD +1
Use of epitopes inducing specific tolerance for the prevention of tissue rejection
The present invention relates to a composition for use in the prevention of the rejection of skin tissue, comprising an effective amount of a peptide comprising an epitope of an antigen selected from the group of the polypeptides type XVII collagen, VII collagen, integrin alpha 6, integrin beta 4, chains of laminin, chains of laminin 322, type IV collagen, plectin, plakoglobin, bullous pemphigoid antigen 1, periplakin, envoplakin, desmoglein 1, desmoglein 3, a desmocollin and human bullous pemphigoid antigen 2 (hBPAG2) wherein said epitope induces immunological tolerance against its underlying polypeptide, and / or a nucleic acid for expressing a peptide comprising an epitope of said antigen as well as a gene therapy based on the composition, in the context of autoimmune blistering diseases, such as bullous pemphigoid or genetic skin diseases such as epidermolysisbullosa.
Owner:BAUER +3
Composition for inhibiting melanin deposition and its application
The invention relates to a composition for inhibiting melanin pigmentation and an application thereof. The composition comprises nicotinamide, inositol, papain and hesperidin extract products, The composition employs nicotinamide and inositol for blocking melanin and transferring black particles to cutin cells through dendritic cells, keratinocyte metabolism is accelerated; lipid-coated papain is employed, peeling and removal of dead cells on a cutin surface layer can be promoted, the melanin is discharged with shedding of cutin cells, update of the cuticle cells is excited; the hesperidin extract product can enhance the function for beautifying the skin, the cornification cellular structure is lifted, desmoplakin and keratin distribution can be improved, and the expression of CASEPASE-14 protein is promoted.
Owner:HUNAN YUJIA COSMETICS MFG CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com